Literature DB >> 16078640

P53 mutations in hepatocellular carcinoma patients in Egypt.

Sherif A El-Kafrawy1, Mohamed Abdel-Hamid, Mai El-Daly, Ola Nada, Alaa Ismail, Sameera Ezzat, Soheir Abdel-Latif, Amany Abdel-Hamid, Peter G Shields, Christopher Loffredo.   

Abstract

The p53 gene plays a major role in hepatocellular carcinoma (HCC). Acquired mutations may provide clues to etiology, as some carcinogenic agents are associated with specific genetic changes in p53. Our aim was to analyze the spectrum of p53 mutations in tumor tissues from subjects with HCC in Egypt, where there is a rising incidence of HCC due to hepatitis C virus (HCV). We collected tumor tissues from 41 subjects with HCC diagnosed at the National Cancer Institute of Cairo University during 2000-2003. Sequence mutations were analyzed by the Affymetrix GeneChip technique. HCV RNA was detected in the sera of 37 subjects (90%). Only one patient had a current HBV infection. A total of 17 of the 41 subjects (41%) had p53 mutations. Thirteen of these were in exon 7, of which 10 were in codon 249, but only 8 of the 10 were the R249S mutation, previously reported to be associated with aflatoxin exposure. The other three exon 7 mutations were found in codons 232, 242 and 248. A total of three mutations were detected in exon 5 codons 133, 144 and 176. One mutation was detected in exon 8 codon 275. Unlike previous studies, this population is characterized by a high prevalence of chronic HCV infection. The presence of the R249S mutation in exon 7 may indicate that these subjects with HCC have been exposed to aflatoxin (AFB1), and further investigation is in progress to measure AFB1-albumin adducts in the sera of these subjects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16078640     DOI: 10.1016/j.ijheh.2005.02.002

Source DB:  PubMed          Journal:  Int J Hyg Environ Health        ISSN: 1438-4639            Impact factor:   5.840


  8 in total

1.  Epidemiologic risk factors of hepatocellular carcinoma in a rural region of Egypt.

Authors:  Amr S Soliman; Chu-Wei Hung; Alexander Tsodikov; Ibrahim A Seifeldin; Mohamed Ramadan; Dina Al-Gamal; Emily L Schiefelbein; Priyanka Thummalapally; Subhojit Dey; Kadry Ismail
Journal:  Hepatol Int       Date:  2010-08-19       Impact factor: 6.047

2.  Assessment of the Proliferative Marker Ki-67 and p53 Protein Expression in HBV- and HCV-related Hepatocellular Carcinoma Cases in Egypt.

Authors:  Waleed S Mohamed; Masoud M Omar; Tarek M Khayri; Ibrahim M Fakhr
Journal:  Int J Health Sci (Qassim)       Date:  2008-01

Review 3.  Genomics in Egypt: Current Status and Future Aspects.

Authors:  Eman Ahmed El-Attar; Rasha Mohamed Helmy Elkaffas; Sarah Ahmed Aglan; Iman S Naga; Amira Nabil; Hoda Y Abdallah
Journal:  Front Genet       Date:  2022-05-13       Impact factor: 4.772

4.  Global geographical overlap of aflatoxin and hepatitis C: controlling risk factors for liver cancer worldwide.

Authors:  D L Palliyaguru; F Wu
Journal:  Food Addit Contam Part A Chem Anal Control Expo Risk Assess       Date:  2013-01-02

Review 5.  A Review of Cancer Genetics and Genomics Studies in Africa.

Authors:  Solomon O Rotimi; Oluwakemi A Rotimi; Bodour Salhia
Journal:  Front Oncol       Date:  2021-02-15       Impact factor: 5.738

6.  Knowledge and perceptions of hepatitis C infection and pesticides use in two rural villages in Egypt.

Authors:  Doa'a A Saleh; Sania Amr; Irene A Jillson; Judy Huei-yu Wang; Walaa A Khairy; Christopher A Loffredo
Journal:  BMC Public Health       Date:  2014-05-24       Impact factor: 3.295

Review 7.  Relative Importance of Hepatitis B and C Viruses in Hepatocellular Carcinoma in EMRO Countries and the Middle East: A Systematic Review.

Authors:  Seyed Moayed Alavian; Hossein Haghbin
Journal:  Hepat Mon       Date:  2016-03-06       Impact factor: 0.660

Review 8.  Hepatocellular Carcinoma: Tumorigenesis and Prediction Markers.

Authors:  Cornelia Braicu; Claudia Burz; Ioana Berindan-Neagoe; Ovidiu Balacescu; Florin Graur; Victor Cristea; Alexandru Irimie
Journal:  Gastroenterology Res       Date:  2009-07-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.